Effect of Urolithin A on Blood Flow in Obese Middle-aged Adults
Urolithin A Supplementation to Improve Endothelial and Cerebrovascular Function in Middle-aged Adults With Obesity
This study is testing if a dietary supplement called urolithin A can improve blood flow and vascular health in middle-aged adults who are obese.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 54 (estimated) |
| Ages | 40 Years to 64 Years |
| Sex | All |
| Sponsor | University of Oklahoma Academic / other |
| Locations | 1 site (Oklahoma City, Oklahoma) |
| Trial ID | NCT05921266 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the impact of urolithin A, a dietary supplement, on blood flow in middle-aged adults with obesity. Participants aged 40-64 with a BMI of 30 or greater will take either urolithin A or a placebo daily for four weeks. The study will assess changes in endothelial function and blood flow through various measurements and blood samples taken at the beginning and end of the trial. The goal is to determine if urolithin A can improve vascular health in this population.
Who should consider this trial
Good fit: Ideal candidates are middle-aged adults aged 40-64 with a body mass index of 30 kg/m2 or greater.
Not a fit: Patients with uncontrolled hypertension, significant cardiac disease, or a history of neurodegenerative disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to a new dietary intervention for improving vascular health in middle-aged adults with obesity.
How similar studies have performed: While the specific effects of urolithin A on blood flow in this demographic are novel, similar studies have shown promise in using dietary supplements to improve vascular health.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 40-64 years old, inclusive * Obesity \[BMI ≥30 kg/m2\] * Ability to read, write, and speak English * Competence to provide written informed consent Exclusion Criteria: * Pregnant or breastfeeding women, or women who intend to become pregnant within the study period * History of uncontrolled hypertension * History of uncontrolled type 1 or type 2 diabetes mellitus * Significant cardiac disease or chest pain in the last 6 months * History of untreated depression or anxiety * History of cognitive impairment * History of uncontrolled significant GI disease (e.g., IBS, Crohn's disease) * Allergy or intolerance to one or more of the intervention components * Undergoing treatment for active cancer * History of neurodegenerative disorders (e.g., multiple sclerosis) * Presence of any condition affecting swallowing ability * Any other medical condition that the investigators deem would adversely affect the participant's safety or ability to complete the study
Where this trial is running
Oklahoma City, Oklahoma
- Translational GeroScience Laboratory - O'Donoghue Research Building — Oklahoma City, Oklahoma, United States (Recruiting)
Study contacts
- Principal investigator: Andriy Yabluchanskiy, MD, PhD — University of Oklahoma Health Science Center
- Study coordinator: Andriy Yabluchanskiy, MD, PhD
- Email: andriy-yabluchanskiy@ouhsc.edu
- Phone: 405-271-8000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.